世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

薬物リハビリテーション薬の世界市場成長 2023-2029


Global Drug Rehabilitation Drugs Market Growth 2023-2029

LPI(LPインフォメーション)の最新調査によると、世界の薬物リハビリテーション薬の市場規模は2022年に1億6,200万米ドルと評価されました。下流市場での需要拡大に伴い、薬物リハビリテーション薬の再調整市場規... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2023年12月4日 US$3,660
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
117 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

LPI(LPインフォメーション)の最新調査によると、世界の薬物リハビリテーション薬の市場規模は2022年に1億6,200万米ドルと評価されました。下流市場での需要拡大に伴い、薬物リハビリテーション薬の再調整市場規模は2029年までに2億5,050万米ドルになると予測され、レビュー期間中の年平均成長率は6.6%です。
この調査レポートは、世界の薬物リハビリテーション薬市場の成長可能性を明らかにしています。薬物リハビリテーション薬は、今後の市場でも安定した成長が見込まれる。しかし、製品の差別化、コストの削減、サプライチェーンの最適化は、薬物リハビリテーション薬の普及にとって引き続き重要です。市場プレーヤーは、研究開発への投資、戦略的パートナーシップの構築、消費者の嗜好の進化に合わせた製品の提供など、薬物リハビリテーション薬市場がもたらす大きなチャンスを生かす必要があります。
解毒剤の開発動向は、主に以下の側面から影響を受けます:
薬物治療の代替と統合:薬物治療の代替と統合:薬物治療において、薬物代替療法と乾式解毒は薬物中毒者の解毒を成功させることができるが、完全に解毒することはできない。そのため、薬物治療は総合的で多様化する必要があり、異なる種類の薬物治療、心理療法、行動療法などを利用する必要がある。
新しい解毒薬の開発科学技術の絶え間ない進歩に伴い、新しい解毒薬の開発も進んでいる。これらの新薬には、オピオイド系および非オピオイド系の解毒薬や、免疫療法や遺伝子治療などの非薬物療法が含まれる。
個別化治療の必要性体調や薬物離脱の状況は人それぞれ異なるため、それぞれの特性に合わせた個別化治療が必要である。今後、解毒医療機関は患者の個人的な状況にもっと注目し、もっと個人化された治療計画を立てる。
薬物治療サービスの普及と標準化:社会が発展し、人々の薬物の害に対する理解が深まるにつれて、薬物治療サービスに対する需要が増加し続ける。将来、薬物治療サービスはより大衆化、標準化され、より多くの人々に認められ、受け入れられるようになる。
つまり、解毒薬の発展傾向は、薬物治療の代替と統合、新しい解毒薬の開発、個別化治療の需要、解毒サービスの普及と標準化に向かっている。
主な特徴
薬物リハビリテーション薬市場に関するレポートは、様々な側面を反映し、業界に関する貴重な洞察を提供します。
市場規模と成長:この調査レポートは、薬物リハビリテーション薬市場の現在の規模と成長の概要を提供します。過去データ、タイプ別市場区分(オピオイド、非オピオイド薬など)、地域別内訳などが含まれます。
市場促進要因と課題:政府規制、環境問題、技術の進歩、消費者の嗜好の変化など、薬物リハビリテーション薬市場の成長を促進する要因を特定・分析することができます。また、インフラの制限、射程距離への不安、初期コストの高さなど、業界が直面する課題も浮き彫りにすることができます。
競合情勢:この調査レポートは、薬物リハビリテーション薬市場内の競合状況の分析を提供しています。主要企業のプロフィール、市場シェア、戦略、製品提供などが含まれます。また、新興企業やその市場に与える潜在的な影響にもスポットを当てています。
技術開発:調査レポートは、薬物リハビリテーション薬業界における最新の技術開発を掘り下げることができます。これには、薬物リハビリテーション薬の技術の進歩、薬物リハビリテーション薬の新規参入、薬物リハビリテーション薬の新規投資、薬物リハビリテーション薬の将来を形作るその他の技術革新が含まれます。
川下企業の好み:このレポートは、薬物リハビリテーション薬市場における顧客の購買行動や採用動向を明らかにします。このレポートには、顧客の購買決定、薬物リハビリテーション製品の嗜好に影響を与える要因が含まれています。
政府の政策とインセンティブ調査レポートは、政府の政策やインセンティブが薬物リハビリテーション薬市場に与える影響を分析します。これには、薬物リハビリテーション薬市場の促進を目的とした規制枠組み、補助金、税制優遇措置などの評価が含まれます。また、市場成長促進におけるこれらの政策の有効性も評価します。
環境への影響と持続可能性調査レポートは、薬物リハビリテーション薬市場の環境への影響と持続可能性の側面を評価します。
市場予測と将来展望:実施した分析に基づき、調査レポートは薬物リハビリテーション薬業界の市場予測と展望を提供します。これには、市場規模、成長率、地域動向、技術進歩や政策展開に関する予測などが含まれます。
提言と機会本レポートでは最後に、業界関係者、政策立案者、投資家への提言を行っています。市場関係者が新たなトレンドを活用し、課題を克服し、薬物リハビリテーション薬市場の成長と発展に貢献するための潜在的な機会を強調しています。
市場の細分化
薬物リハビリテーション薬市場は、タイプ別と用途別に分類されます。2018年から2029年までの期間について、セグメント間の成長により、タイプ別、用途別の消費額の正確な計算と予測を数量と金額で提供します。
タイプ別セグメント
オピオイド薬
非オピオイド薬
用途別セグメント
病院
クリニック
本レポートでは、市場を地域別にも分割しています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
テバ
パデュー・ファーマ
マリンクロッド
アムニール・ファーマ
コレギウム
J&J
エンドー
ファイザー
インシス
マイラン
ヒグマ
エガレット
本レポートで扱う主な質問
世界の薬物リハビリテーション薬市場の10年見通しは?
世界および地域別に、薬物リハビリテーション薬市場の成長を促進する要因は何か?
市場別、地域別に最も急成長する技術は何か?
薬物リハビリテーション薬の市場機会は最終市場規模によってどのように異なりますか?
薬物リハビリテーション薬のタイプ、用途別の内訳は?


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Drug Rehabilitation Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Drug Rehabilitation Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Drug Rehabilitation Drugs by Country/Region, 2018, 2022 & 2029
2.2 Drug Rehabilitation Drugs Segment by Type
2.2.1 Opioids
2.2.2 Non-opioid Drugs
2.3 Drug Rehabilitation Drugs Sales by Type
2.3.1 Global Drug Rehabilitation Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Drug Rehabilitation Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Drug Rehabilitation Drugs Sale Price by Type (2018-2023)
2.4 Drug Rehabilitation Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Drug Rehabilitation Drugs Sales by Application
2.5.1 Global Drug Rehabilitation Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Drug Rehabilitation Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Drug Rehabilitation Drugs Sale Price by Application (2018-2023)
3 Global Drug Rehabilitation Drugs by Company
3.1 Global Drug Rehabilitation Drugs Breakdown Data by Company
3.1.1 Global Drug Rehabilitation Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Drug Rehabilitation Drugs Sales Market Share by Company (2018-2023)
3.2 Global Drug Rehabilitation Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Drug Rehabilitation Drugs Revenue by Company (2018-2023)
3.2.2 Global Drug Rehabilitation Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Drug Rehabilitation Drugs Sale Price by Company
3.4 Key Manufacturers Drug Rehabilitation Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Drug Rehabilitation Drugs Product Location Distribution
3.4.2 Players Drug Rehabilitation Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Drug Rehabilitation Drugs by Geographic Region
4.1 World Historic Drug Rehabilitation Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Drug Rehabilitation Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Drug Rehabilitation Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Drug Rehabilitation Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Drug Rehabilitation Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Drug Rehabilitation Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Drug Rehabilitation Drugs Sales Growth
4.4 APAC Drug Rehabilitation Drugs Sales Growth
4.5 Europe Drug Rehabilitation Drugs Sales Growth
4.6 Middle East & Africa Drug Rehabilitation Drugs Sales Growth
5 Americas
5.1 Americas Drug Rehabilitation Drugs Sales by Country
5.1.1 Americas Drug Rehabilitation Drugs Sales by Country (2018-2023)
5.1.2 Americas Drug Rehabilitation Drugs Revenue by Country (2018-2023)
5.2 Americas Drug Rehabilitation Drugs Sales by Type
5.3 Americas Drug Rehabilitation Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drug Rehabilitation Drugs Sales by Region
6.1.1 APAC Drug Rehabilitation Drugs Sales by Region (2018-2023)
6.1.2 APAC Drug Rehabilitation Drugs Revenue by Region (2018-2023)
6.2 APAC Drug Rehabilitation Drugs Sales by Type
6.3 APAC Drug Rehabilitation Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Drug Rehabilitation Drugs by Country
7.1.1 Europe Drug Rehabilitation Drugs Sales by Country (2018-2023)
7.1.2 Europe Drug Rehabilitation Drugs Revenue by Country (2018-2023)
7.2 Europe Drug Rehabilitation Drugs Sales by Type
7.3 Europe Drug Rehabilitation Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Drug Rehabilitation Drugs by Country
8.1.1 Middle East & Africa Drug Rehabilitation Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Drug Rehabilitation Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Drug Rehabilitation Drugs Sales by Type
8.3 Middle East & Africa Drug Rehabilitation Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Drug Rehabilitation Drugs
10.3 Manufacturing Process Analysis of Drug Rehabilitation Drugs
10.4 Industry Chain Structure of Drug Rehabilitation Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Drug Rehabilitation Drugs Distributors
11.3 Drug Rehabilitation Drugs Customer
12 World Forecast Review for Drug Rehabilitation Drugs by Geographic Region
12.1 Global Drug Rehabilitation Drugs Market Size Forecast by Region
12.1.1 Global Drug Rehabilitation Drugs Forecast by Region (2024-2029)
12.1.2 Global Drug Rehabilitation Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Drug Rehabilitation Drugs Forecast by Type
12.7 Global Drug Rehabilitation Drugs Forecast by Application
13 Key Players Analysis
13.1 Teva
13.1.1 Teva Company Information
13.1.2 Teva Drug Rehabilitation Drugs Product Portfolios and Specifications
13.1.3 Teva Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Teva Main Business Overview
13.1.5 Teva Latest Developments
13.2 Purdue Pharma
13.2.1 Purdue Pharma Company Information
13.2.2 Purdue Pharma Drug Rehabilitation Drugs Product Portfolios and Specifications
13.2.3 Purdue Pharma Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Purdue Pharma Main Business Overview
13.2.5 Purdue Pharma Latest Developments
13.3 Mallinckrodt
13.3.1 Mallinckrodt Company Information
13.3.2 Mallinckrodt Drug Rehabilitation Drugs Product Portfolios and Specifications
13.3.3 Mallinckrodt Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Mallinckrodt Main Business Overview
13.3.5 Mallinckrodt Latest Developments
13.4 Amneal Pharma
13.4.1 Amneal Pharma Company Information
13.4.2 Amneal Pharma Drug Rehabilitation Drugs Product Portfolios and Specifications
13.4.3 Amneal Pharma Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Amneal Pharma Main Business Overview
13.4.5 Amneal Pharma Latest Developments
13.5 Collegium
13.5.1 Collegium Company Information
13.5.2 Collegium Drug Rehabilitation Drugs Product Portfolios and Specifications
13.5.3 Collegium Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Collegium Main Business Overview
13.5.5 Collegium Latest Developments
13.6 J&J
13.6.1 J&J Company Information
13.6.2 J&J Drug Rehabilitation Drugs Product Portfolios and Specifications
13.6.3 J&J Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 J&J Main Business Overview
13.6.5 J&J Latest Developments
13.7 Endo
13.7.1 Endo Company Information
13.7.2 Endo Drug Rehabilitation Drugs Product Portfolios and Specifications
13.7.3 Endo Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Endo Main Business Overview
13.7.5 Endo Latest Developments
13.8 Pfizer
13.8.1 Pfizer Company Information
13.8.2 Pfizer Drug Rehabilitation Drugs Product Portfolios and Specifications
13.8.3 Pfizer Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Pfizer Main Business Overview
13.8.5 Pfizer Latest Developments
13.9 INSYS
13.9.1 INSYS Company Information
13.9.2 INSYS Drug Rehabilitation Drugs Product Portfolios and Specifications
13.9.3 INSYS Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 INSYS Main Business Overview
13.9.5 INSYS Latest Developments
13.10 Mylan
13.10.1 Mylan Company Information
13.10.2 Mylan Drug Rehabilitation Drugs Product Portfolios and Specifications
13.10.3 Mylan Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Mylan Main Business Overview
13.10.5 Mylan Latest Developments
13.11 Hikma
13.11.1 Hikma Company Information
13.11.2 Hikma Drug Rehabilitation Drugs Product Portfolios and Specifications
13.11.3 Hikma Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Hikma Main Business Overview
13.11.5 Hikma Latest Developments
13.12 Egalet
13.12.1 Egalet Company Information
13.12.2 Egalet Drug Rehabilitation Drugs Product Portfolios and Specifications
13.12.3 Egalet Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Egalet Main Business Overview
13.12.5 Egalet Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

According to our LPI (LP Information) latest study, the global Drug Rehabilitation Drugs market size was valued at US$ 1620 million in 2022. With growing demand in downstream market, the Drug Rehabilitation Drugs is forecast to a readjusted size of US$ 2540.5 million by 2029 with a CAGR of 6.6% during review period.
The research report highlights the growth potential of the global Drug Rehabilitation Drugs market. Drug Rehabilitation Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Drug Rehabilitation Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Drug Rehabilitation Drugs market.
The development trend of detoxification drugs is mainly affected by the following aspects:
Substitution and integration of drug treatment: In drug treatment, drug substitution therapy and dry detoxification can help drug addicts successfully detoxify, but they cannot completely detoxify. Therefore, drug treatment needs to be comprehensive and diversified, including the use of different types of drug treatment, psychotherapy, behavioral therapy, etc.
Development of new detoxification drugs: With the continuous advancement of science and technology, the development of new detoxification drugs is also ongoing. These new drugs include opioid and non-opioid detoxification drugs, as well as non-drug treatments such as immunotherapy and gene therapy.
Need for personalized treatment: Everyone’s physical condition and drug withdrawal situation are different, so personalized treatment needs to be tailored to each person’s characteristics. In the future, detoxification medical institutions will pay more attention to patients' personal conditions and develop more personalized treatment plans.
Popularization and standardization of drug treatment services: As society develops and people's understanding of the harm of drugs continues to deepen, the demand for drug treatment services will continue to increase. In the future, drug treatment services will become more popularized and standardized, and will be recognized and accepted by more people.
In short, the development trend of detoxification drugs will be towards the substitution and integration of drug treatment, the development of new detoxification drugs, the demand for personalized treatment, and the popularization and standardization of detoxification services.
Key Features:
The report on Drug Rehabilitation Drugs market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Drug Rehabilitation Drugs market. It may include historical data, market segmentation by Type (e.g., Opioids, Non-opioid Drugs), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Drug Rehabilitation Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Drug Rehabilitation Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Drug Rehabilitation Drugs industry. This include advancements in Drug Rehabilitation Drugs technology, Drug Rehabilitation Drugs new entrants, Drug Rehabilitation Drugs new investment, and other innovations that are shaping the future of Drug Rehabilitation Drugs.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Drug Rehabilitation Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Drug Rehabilitation Drugs product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Drug Rehabilitation Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Drug Rehabilitation Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Drug Rehabilitation Drugs market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Drug Rehabilitation Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Drug Rehabilitation Drugs market.
Market Segmentation:
Drug Rehabilitation Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Opioids
Non-opioid Drugs
Segmentation by application
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva
Purdue Pharma
Mallinckrodt
Amneal Pharma
Collegium
J&J
Endo
Pfizer
INSYS
Mylan
Hikma
Egalet
Key Questions Addressed in this Report
What is the 10-year outlook for the global Drug Rehabilitation Drugs market?
What factors are driving Drug Rehabilitation Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Drug Rehabilitation Drugs market opportunities vary by end market size?
How does Drug Rehabilitation Drugs break out type, application?



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Drug Rehabilitation Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Drug Rehabilitation Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Drug Rehabilitation Drugs by Country/Region, 2018, 2022 & 2029
2.2 Drug Rehabilitation Drugs Segment by Type
2.2.1 Opioids
2.2.2 Non-opioid Drugs
2.3 Drug Rehabilitation Drugs Sales by Type
2.3.1 Global Drug Rehabilitation Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Drug Rehabilitation Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Drug Rehabilitation Drugs Sale Price by Type (2018-2023)
2.4 Drug Rehabilitation Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Drug Rehabilitation Drugs Sales by Application
2.5.1 Global Drug Rehabilitation Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Drug Rehabilitation Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Drug Rehabilitation Drugs Sale Price by Application (2018-2023)
3 Global Drug Rehabilitation Drugs by Company
3.1 Global Drug Rehabilitation Drugs Breakdown Data by Company
3.1.1 Global Drug Rehabilitation Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Drug Rehabilitation Drugs Sales Market Share by Company (2018-2023)
3.2 Global Drug Rehabilitation Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Drug Rehabilitation Drugs Revenue by Company (2018-2023)
3.2.2 Global Drug Rehabilitation Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Drug Rehabilitation Drugs Sale Price by Company
3.4 Key Manufacturers Drug Rehabilitation Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Drug Rehabilitation Drugs Product Location Distribution
3.4.2 Players Drug Rehabilitation Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Drug Rehabilitation Drugs by Geographic Region
4.1 World Historic Drug Rehabilitation Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Drug Rehabilitation Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Drug Rehabilitation Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Drug Rehabilitation Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Drug Rehabilitation Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Drug Rehabilitation Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Drug Rehabilitation Drugs Sales Growth
4.4 APAC Drug Rehabilitation Drugs Sales Growth
4.5 Europe Drug Rehabilitation Drugs Sales Growth
4.6 Middle East & Africa Drug Rehabilitation Drugs Sales Growth
5 Americas
5.1 Americas Drug Rehabilitation Drugs Sales by Country
5.1.1 Americas Drug Rehabilitation Drugs Sales by Country (2018-2023)
5.1.2 Americas Drug Rehabilitation Drugs Revenue by Country (2018-2023)
5.2 Americas Drug Rehabilitation Drugs Sales by Type
5.3 Americas Drug Rehabilitation Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Drug Rehabilitation Drugs Sales by Region
6.1.1 APAC Drug Rehabilitation Drugs Sales by Region (2018-2023)
6.1.2 APAC Drug Rehabilitation Drugs Revenue by Region (2018-2023)
6.2 APAC Drug Rehabilitation Drugs Sales by Type
6.3 APAC Drug Rehabilitation Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Drug Rehabilitation Drugs by Country
7.1.1 Europe Drug Rehabilitation Drugs Sales by Country (2018-2023)
7.1.2 Europe Drug Rehabilitation Drugs Revenue by Country (2018-2023)
7.2 Europe Drug Rehabilitation Drugs Sales by Type
7.3 Europe Drug Rehabilitation Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Drug Rehabilitation Drugs by Country
8.1.1 Middle East & Africa Drug Rehabilitation Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Drug Rehabilitation Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Drug Rehabilitation Drugs Sales by Type
8.3 Middle East & Africa Drug Rehabilitation Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Drug Rehabilitation Drugs
10.3 Manufacturing Process Analysis of Drug Rehabilitation Drugs
10.4 Industry Chain Structure of Drug Rehabilitation Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Drug Rehabilitation Drugs Distributors
11.3 Drug Rehabilitation Drugs Customer
12 World Forecast Review for Drug Rehabilitation Drugs by Geographic Region
12.1 Global Drug Rehabilitation Drugs Market Size Forecast by Region
12.1.1 Global Drug Rehabilitation Drugs Forecast by Region (2024-2029)
12.1.2 Global Drug Rehabilitation Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Drug Rehabilitation Drugs Forecast by Type
12.7 Global Drug Rehabilitation Drugs Forecast by Application
13 Key Players Analysis
13.1 Teva
13.1.1 Teva Company Information
13.1.2 Teva Drug Rehabilitation Drugs Product Portfolios and Specifications
13.1.3 Teva Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Teva Main Business Overview
13.1.5 Teva Latest Developments
13.2 Purdue Pharma
13.2.1 Purdue Pharma Company Information
13.2.2 Purdue Pharma Drug Rehabilitation Drugs Product Portfolios and Specifications
13.2.3 Purdue Pharma Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Purdue Pharma Main Business Overview
13.2.5 Purdue Pharma Latest Developments
13.3 Mallinckrodt
13.3.1 Mallinckrodt Company Information
13.3.2 Mallinckrodt Drug Rehabilitation Drugs Product Portfolios and Specifications
13.3.3 Mallinckrodt Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Mallinckrodt Main Business Overview
13.3.5 Mallinckrodt Latest Developments
13.4 Amneal Pharma
13.4.1 Amneal Pharma Company Information
13.4.2 Amneal Pharma Drug Rehabilitation Drugs Product Portfolios and Specifications
13.4.3 Amneal Pharma Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Amneal Pharma Main Business Overview
13.4.5 Amneal Pharma Latest Developments
13.5 Collegium
13.5.1 Collegium Company Information
13.5.2 Collegium Drug Rehabilitation Drugs Product Portfolios and Specifications
13.5.3 Collegium Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Collegium Main Business Overview
13.5.5 Collegium Latest Developments
13.6 J&J
13.6.1 J&J Company Information
13.6.2 J&J Drug Rehabilitation Drugs Product Portfolios and Specifications
13.6.3 J&J Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 J&J Main Business Overview
13.6.5 J&J Latest Developments
13.7 Endo
13.7.1 Endo Company Information
13.7.2 Endo Drug Rehabilitation Drugs Product Portfolios and Specifications
13.7.3 Endo Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Endo Main Business Overview
13.7.5 Endo Latest Developments
13.8 Pfizer
13.8.1 Pfizer Company Information
13.8.2 Pfizer Drug Rehabilitation Drugs Product Portfolios and Specifications
13.8.3 Pfizer Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Pfizer Main Business Overview
13.8.5 Pfizer Latest Developments
13.9 INSYS
13.9.1 INSYS Company Information
13.9.2 INSYS Drug Rehabilitation Drugs Product Portfolios and Specifications
13.9.3 INSYS Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 INSYS Main Business Overview
13.9.5 INSYS Latest Developments
13.10 Mylan
13.10.1 Mylan Company Information
13.10.2 Mylan Drug Rehabilitation Drugs Product Portfolios and Specifications
13.10.3 Mylan Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Mylan Main Business Overview
13.10.5 Mylan Latest Developments
13.11 Hikma
13.11.1 Hikma Company Information
13.11.2 Hikma Drug Rehabilitation Drugs Product Portfolios and Specifications
13.11.3 Hikma Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Hikma Main Business Overview
13.11.5 Hikma Latest Developments
13.12 Egalet
13.12.1 Egalet Company Information
13.12.2 Egalet Drug Rehabilitation Drugs Product Portfolios and Specifications
13.12.3 Egalet Drug Rehabilitation Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Egalet Main Business Overview
13.12.5 Egalet Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります


よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/15 10:26

157.84 円

166.62 円

202.61 円

ページTOPに戻る